Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 8, 2015, Pages 1506-1514

  Cieri, Nicoletta ^a,b   Greco, Raffaella ^a   Crucitti, Lara ^a,b   Morelli, Mara ^a   Giglio, Fabio ^a   Levati, Giorgia ^a,b   Assanelli, Andrea ^a   Carrabba, Matteo G ^a   Bellio, Laura ^a   Milani, Raffaella ^a   Lorentino, Francesca ^a   Stanghellini, Maria Teresa Lupo ^a   De Freitas, Tiago ^a   Marktel, Sarah ^a   Bernardi, Massimo ^a   Corti, Consuelo ^a   Vago, Luca ^a   Bonini, Chiara ^a   Ciceri, Fabio ^a   Peccatori, Jacopo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Allogeneic stem cell transplantation; Haploidentical transplantation; Peripheral blood stem cell transplantation; Post transplantation cyclophosphamide; Sirolimus

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MYCOPHENOLATE MOFETIL; POST TRANSPLANTATION CYCLOPHOSPHAMIDE; RAPAMYCIN; TACROLIMUS; TREOSULFAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BUSULFAN; MYELOABLATIVE AGENT;

ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENCEPHALITIS; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INVESTIGATIVE PROCEDURES; LUNG TUBERCULOSIS; LYMPHOCYTE SUBPOPULATION; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYOCARDITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; REMISSION; SYSTEMIC MYCOSIS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SIROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937726953     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.04.025     Document Type: Article

References (63)

1. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
2. Reisner Y., Hagin D., Martelli M.F. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011, 118:6006-6017.
3. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. NEngl J Med 1985, 313:765-771.
4. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. NEngl J Med 1998, 339:1186-1193.
5. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. JClin Oncol 2005, 23:3447-3454.
6. Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 2012, 39:664-673.
7. Ciceri F., Bonini C., Stanghellini M.T.L., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009, 10:489-500.
8. Di Bartolomeo P., Santarone S., De Angelis G., et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013, 121:849-857.
9. Huang X.-J., Liu D.-H., Liu K.-Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
10. Peccatori J., Forcina A., Clerici D., et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the invivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015, 29:396-405.
11. Fuchs E.J. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol 2012, 19:440-447.
12. Luznik L., Fuchs E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010, 47:65-77.
13. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
14. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
15. Raj K., Pagliuca A., Bradstock K., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014, 20:890-895.
16. Bhamidipati P.K., DiPersio J.F., Stokerl-Goldstein K., et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 2014, 49:1124-1126.
17. Castagna L., Crocchiolo R., Furst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-729.
18. Raiola A.M., Dominietto A., Ghiso A., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013, 19:117-122.
19. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
20. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
21. Schneidawind D., Pierini A., Negrin R.S. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood 2013, 122:3116-3121.
22. Coenen J.J.A., Koenen H.J.P.M., van Rijssen E., et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007, 39:537-545.
23. Kanakry C.G., Ganguly S., Zahurak M., et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Translational Med 2013, 5:211ra157.
24. Ganguly S., Ross D.B., Panoskaltsis-Mortari A., et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 2014, 124:2131-2141.
25. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
26. Monti P., Mercalli A., Leone B.E., et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75:137-145.
27. Hackstein H., Taner T., Zahorchak A.F., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation invitro and dendritic cell mobilization and function invivo. Blood 2003, 101:4457-4463.
28. Hackstein H., Taner T., Logar A.J., Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100:1084-1087.
29. Jain S., Bicknell G.R., Whiting P.H., Nicholson M.L. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 2001, 33:556-558.
30. Patsenker E., Schneider V., Ledermann M., et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. JHepatol 2011, 55:388-398.
31. Marty F.M., Bryar J., Browne S.K., et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110:490-500.
32. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. JClin Oncol 2008, 26:5767-5774.
33. Récher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
34. Sillaber C., Mayerhofer M., Böhm A., et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008, 38:43-52.
35. Follo M.Y., Mongiorgi S., Bosi C., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67:4287-4294.
36. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
37. Sorror M.L., Storb R.F., Sandmaier B.M., et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. JClin Oncol 2014, 32:3249-3256.
38. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
39. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:471-482.
40. Maertens J., Marchetti O., Herbrecht R., et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011, 46:709-718.
41. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
42. Mazzi B., Clerici T.D., Zanussi M., et al. Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia 2008, 22:2119-2122.
43. Crucitti L., Crocchiolo R., Toffalori C., et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia 2015, 29:1143-1524.
44. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
45. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
46. Pavletic S.Z., Kumar S., Mohty M., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
47. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
48. Ruutu T., Gratwohl A., de Witte T., et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014, 49:168-173.
49. Scrucca L., Santucci A., Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010, 45:1388-1395.
50. Vago L., Perna S.K., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. NEngl J Med 2009, 361:478-488.
51. Vago L., Toffalori C., Ciceri F., Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol 2012, 39:707-715.
52. Raiola A., Dominietto A., Varaldo R., et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2014, 49:190-194.
53. Symons H.J., Chen A., Gamper C., et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant 2015, 21:S29.
54. Crocchiolo R., Bramanti S., Vai A., et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015, 17:242-249.
55. Cieri N., Oliveira G., Greco R., et al. Generation of human memory stem T cells upon haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015, 125:2865-2874.
56. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996, 195:129-139.
57. Amir A.L., D'Orsogna L.J.A., Roelen D.L., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
58. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
59. Rieger K., Loddenkemper C., Maul J., et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006, 107:1717-1723.
60. Christopeit M., Kuss O., Finke J., et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. JClin Oncol 2013, 31:3259-3271.
61. Tischer J., Engel N., Fritsch S., et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant 2014, 49:895-901.
62. Yeh S.-P., Lin C.-C., Lin C.-H., et al. Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2015, [Epub ahead of print]. 10.1038/bmt.2015.67.
63. Horstmann K., Boumendil A., Finke J., et al. Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplant 2015, 50:790-794.